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Abstract
The constraint values of dose-volume histogram (DVH) parameters for radiation pneumoni-
tis (RP) prediction have not been uniform in previous studies. We compared the differences
between conventional DVH parameters and DVH parameters with high attenuation volume
(HAV) in CT imaging in both esophageal cancer and lung cancer patients to determine the
most suitable DVH parameters in predicting RP onset. Seventy-seven and 72 patients who
underwent radiation therapy for lung cancer and esophageal cancer, respectively, were ret-
rospectively assessed. RP was valued according to the Common Terminology Criteria for
Adverse Events. We quantified HAV with quantitative computed tomography analysis. We
compared conventional DVH parameters and DVH parameters with HAV in both groups of
patients. Then, the thresholds of DVH parameters that predicted symptomatic RP and the
differences in threshold of DVH parameters between lung cancer and esophageal cancer
patient groups were compared. The predictive performance of DVH parameters for symp-
tomatic RP was compared using the area under the receiver operating characteristic curve.
Mean lung dose, HAV30% (the proportion of the lung with HAV receiving�30 Gy), and
HAV20% were the top three parameters in lung cancer, while HAV10%, HAV5%, and V10
(the percentage of lung volume receiving 10 Gy or more) were the top three in esophageal
cancer. By comparing the differences in the threshold for parameters predicting RP between
the two cancers, we saw that HAV30% retained the same value in both cancers. DVH
parameters with HAV showed narrow differences in the threshold between the two cancer
patient groups compared to conventional DVH parameters. DVH parameters with HAV may
have higher commonality than conventional DVH parameters in both patient groups tested.
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Introduction
Radiation pneumonitis (RP) is a serious adverse effect of radiation therapy; symptomatic
pneumonitis particularly negatively influences chemotherapy after radiotherapy. Therefore,
the prediction and prevention of symptomatic RP are very significant. Even among lung can-
cer patients alone, various threshold values of DVH parameters have been reported for the pre-
diction of RP [1–3]. Thus, guidelines for thoracic radiotherapy have set constraint values for
traditional DVH parameters such as the mean lung dose (MLD) (20−23 Gy) and the percent-
age of lung volume receiving 20 Gy or more (V20) (30−40%) to reduce the risk of RP [4–8].
We recently showed that DVH parameters calculated using only volumes of high attenuation
in CT imaging by excluding emphysematous lesions were better predictors of RP than tradi-
tional parameters [9]. However, little has been reported on the threshold values of DVH
parameters for the prediction of RP in different types of cancers. Threshold values that are
closer or the same in different types of cancers would be more reliable and versatile. We com-
pared the performances of our new DVH parameters with traditional parameters in predicting
RP in both esophageal cancer patients and lung cancer patients to evaluate whether our new
DVH parameters could predict RP more accurately, without varying threshold values among
different types of cancer.
Methods and materials
Study design
This study was a single-center, retrospective, observational study. The endpoint of this analysis
was to evaluate the performance of DVH parameters for the prediction of symptomatic RP of
grade 2 or worse (Common Terminology Criteria for Adverse Events, version 5.0).
Selection of study participants
Patients who received radiotherapy for lung cancer (n = 77) or esophageal cancer (n = 72) at
our institution between June 2010 and July 2017 were selected retrospectively. The inclusion
criteria were as follows: first time receiving radiotherapy, total irradiation dose >30 Gy (frac-
tion dose is 1.8–3.0 Gy), pneumonectomy not performed within 5 months after radiotherapy
or before the occurrence of symptomatic RP, follow-up period >5 months if symptomatic RP
did not occur, and entire lung fields scanned using computed tomography (CT) before radio-
therapy. We excluded patients who underwent stereotactic body radiotherapy. Patients were
treated with either curative or palliative intent with radiotherapy alone or with concurrent
chemoradiation.
Radiotherapy planning and image analysis
Radiotherapy planning was performed as 3D treatment planning using the EclipseTM software
(Varian Medical Systems, Palo Alto, CA, USA) with an analytical anisotropic algorithm, and
the calculation grid was 2.5 mm for the lung. The treatment planning was based on a 1.25-mm
thick CT scans obtained in the treatment position. The resolution of CT scans was 1.25
mm×1.25 mm (field of view = 64 cm, matrix = 512×512 pixels). The distribution of the radia-
tion dose was calculated using lung heterogeneity corrections. The breathing phase of the CT
scan was free breathing. Gating and breath-hold were not used. We evaluated DVH parame-
ters without emphysematous lesions, as previously described [5, 9]. Low attenuation volume
(LAV), which expresses emphysematous lesions in the lung, was assessed using the upper
threshold limit of −856 HU. To further verify the validity of this constraint value, we previ-
ously validated the association between the CT under free-breathing and the inspiratory CT
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performed within 45 days after free-breathing CT [10]. Inspiratory CT was performed using
Toshiba Aquillion ONE (Toshiba Medical Systems Corp., Otawara, Tochigi, Japan), and LAV
was analyzed using Aquarius iNtuitionTM software ver.4.4.12 (TeraRecon Inc., San Mateo,
Calif) and evaluated using the threshold limit of -950 HU. The LAV in inspiratory CT was
highly correlated with the LAV in CT under free breathing. Regarding relative electron den-
sity, −856HU was 0.1488. Since “total lung volume (TLV)–LAV” is equal to high attenuation
volume (HAV)�−856 HU in the lung, we described “TLV–LAV” as HAV in this report (Fig
1). We also defined HAV irradiated at�30 Gy as HAV30 and “HAV30 / TLV” as HAV30%.
We evaluated the DVH parameters that predicted RP more accurately in our previous study
(See S1 Table). The mean high attenuation lung dose (MHALD) was defined as the mean dose
irradiated on a high attenuation lung field.
Clinical toxicity
The severity of RP was assessed retrospectively using the Common Terminology Criteria for
Adverse Events, version 5.0 [11]. Patients were generally followed up for 3 to 6 weeks after the
completion of radiotherapy, and at 3- to 6-month intervals thereafter. The diagnosis of RP and
the evaluation of its severity was performed based on radiographic images, laboratory test
results, physical examination findings, and clinical symptoms, by reviewing medical records.
The study protocol was approved by the Institutional Review Board of the Shiga University
of Medical Science (IRB no. R2014-236).
Statistical analyses
We used summary statistics to analyze clinical factors such as age, sex, disease stage, histologic
type, type of radiotherapy methods, chemotherapy, smoking history, smoking index, body
mass index, and interstitial lung disease (ILD) for all patients. Continuous variables are pre-
sented as medians and ranges, and categorical variables as percentages. We also compared
clinical factors between RP�grade 2 and RP�grade 1 using Wilcoxon’s rank-sum test or
Fisher’s exact test, as appropriate.
Fig 1. Area inside the purple line shows the high attenuation lung using a threshold of –856 HU. The colorful area
represents the irradiated area (red indicates the area with the highest dose, and blue represents the area with the lowest
dose), and the overlaps were calculated.
https://doi.org/10.1371/journal.pone.0244143.g001
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Conventional DVH parameters, including MLD, V2, V5, V10, V20, and V30, and other
DVH parameters of high lung attenuation, are described as medians and interquartile ranges.
Univariate logistic regression analysis was performed to evaluate the association between
each DVH parameter and the onset of symptomatic RP. The predictive performance of each
DVH parameter for RP was compared using the area under the receiver operating characteris-
tic curve (AUC). We identified the optimal decision threshold value of each DVH parameter
with the highest sensitivity and specificity. Statistical analyses were performed using JMP ver-
sion 11 (SAS Institute Inc., Cary, NC, USA) and R version 3.5.1 (R Foundation for Statistical




RP was observed in 43 out of 77 lung cancer patients (grade 1, n = 14; grade 2, n = 13; grade 3,
n = 13; grade 4, n = 1; and grade 5, n = 2) and in 27 out of 72 esophageal cancer patients (grade
1, n = 19; grade 2, n = 3; grade 3, n = 4; grade 4, n = 0; and grade 5, n = 1).
In the univariate analysis of lung cancer patients, concurrent chemotherapy, pre-existing
ILD, MLD, and V20 were significantly correlated with the occurrence of symptomatic RP
(Table 1). In the univariate analysis of esophageal cancer patients, smoking history, MLD, and
V20 were significantly correlated with the occurrence of symptomatic RP (Table 2). Chemo-
therapeutic agents are summarized in S2 Table.
DVH parameters
In both lung cancer and esophageal cancer patients, univariate logistic regression analysis for
symptomatic RP (�grade 2) showed that all DVH parameters were significantly related to
symptomatic RP (See S3 Table). When the predictive performances of DVH parameters for
symptomatic RP were compared using the AUC, MLD, HAV30%, and HAV20% were the
three best parameters in lung cancer and HAV10%, HAV5%, and V10 were the three best in
esophageal cancer (Fig 2). As there were no overlaps between lung cancer and esophageal can-
cer, we compared the thresholds of these parameters for the prediction of RP between the two
forms of cancer (Fig 3). When the differences in threshold of parameters between the two can-
cers were compared, threshold values of HAV30% were found to be almost identical in these
cancers. For all DVH parameters, differences in the threshold between the two cancers were
smaller when considering non-emphysematous (MLHAD, HAV30%, HAV20%, HAV10%,
and HAV5%) than conventional (MLD, V30, V20, V10, and V5) parameters (Fig 4). Boxplots
for each DVH parameter are shown in S1 Fig.
Discussion
V20 or MLD has been commonly used as an index for the prevention of severe RP in practice.
In various clinical applications of radiotherapy, the limit of MLD or V20 has been described
[13–16]. These DVH parameters are simple to calculate and accurate enough for the prediction
of RP but have never been compared with other DVH parameters in this regard. In addition,
the reported threshold values of dose-volume histograms for the prediction of RP have only
been discussed for lung cancer patients [1–3]. We previously showed that DVH parameters
representing irradiated non-emphysematous lung volume were better predictors of RP than
conventional DVH parameters [9]. Little has been reported on the comparison of thresholds
of DVH parameters associated with the onset of RP among different malignant populations.
PLOS ONE Dosimetric parameters with high attenuation
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In this study, we assessed the performance of conventional DVH parameters and some DVH
parameters calculated by excluding emphysematous lesions reported in our previous study
and compared the accuracy using the AUC in esophageal cancer and lung cancer populations.
We found that in each population, DVH parameters with HAV predicted the onset of symp-
tomatic RP more accurately than traditional DVH parameters. In addition, the differences in
the DVH parameters of the two populations with HAV were smaller than those of traditional
DVH parameters. Due to the identical threshold values of HAV30% in these two cancer types,
this one threshold value could be used in common, at least in lung cancer and esophageal
Table 1. Clinical parameters in lung cancer patients with symptomatic and asymptomatic radiation pneumonitis.
Characteristic Symptomatic Patients (N = 29) Asymptomatic Patients (N = 48) P-value
Median age (range), year 69 (57–82) 67 (39–89) 0.678
Male sex 26 (89.6) 40 (83.3) 0.520
Disease stage 0.104
1 0 (0) 5 (10.4)
2 2 (6.9) 3 (6.3)
3 24 (82.8) 29 (60.4)
4 3 (10.3) 11 (22.9)
�Histology type 0.494
SqCC 13 (44.8) 15 (31.2)
Adenocarcinoma 7 (24.1) 13 (27.1)
SCC 7 (24.1) 8 (16.7)
NSCC 2 (6.9) 6 (12.5)
Unknown 0 (0) 4 (8.3)
Others 0 (0) 2 (4.2)
Treatment type 1.000
IMRT 1 (3.5) 3 (6.3)
3D Conformal 28 (96.6) 45 (93.8)
Chemotherapy 0.002
Yes 23 (79.3) 20 (41.7)
No 6 (20.7) 28 (58.3)
Smoking history 0.561
Current 12 (41.4) 14 (29.2)
Former 14 (48.2) 28 (58.3)
Never 3 (10.3) 6 (12.5)
Smoking (range), pack-years 45 (0–120) 42 (0–180) 0.709
Median BMI (range), kg/m2 20.55 (16.19–24.83) 19.47 (14.98–25.42) 0.091
ILD 0.004
Yes 4 (13.8) 0 (0)
No 25 (86.2) 48 (100)
Median MLD (IQR), Gy 13.307 (8.89–17.006) 7.056 (4.123–9.367) <0.0001
Median V20 (IQR) 23.227 (18.047–32.352) 13.554 (7.526–14.423) <0.0001
Median LAV% (IQR) 8.5 (3.6–24.3) 11.1 (2.6–28.5) 0.801
�Percentages in this column may not add up to exactly 100% because of rounding.
Unless otherwise specified, data are expressed as numbers of patients, and numbers in parentheses are percentages. RP = radiation pneumonitis; SqCC = squamous cell
carcinoma; SCC = small cell carcinoma; NSCC = non-small cell carcinoma; IMRT = intensity-modulated radiation therapy; BMI = body mass index; ILD = interstitial
lung disease; MLD = mean lung dose; IQR = interquartile range; V20 = percentage of lung volume irradiated� 20 Gy; LAV% = ratio of low attenuation volume to the
lung volume.
https://doi.org/10.1371/journal.pone.0244143.t001
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cancer. Based on the results presented in this study, we cannot affirm that HAV30% is the best
predictor of RP. Indeed, HAV30% was not among the three parameters when the predictive
performances of DVH parameters for symptomatic RP were compared using the AUC in
esophageal cancer. Moreover, we cannot compare between MLD, MLHAD, and HAV30%,
due to the unit differences. However, HAV might be a better predictor than the traditional
DVH parameters. The frequency of RP was different in the two groups, but the threshold val-
ues were not so different between the groups. This may be because fewer patients with esoph-
ageal cancer received irradiation at high doses than did lung cancer patients. Some studies
showed that chronic obstructive pulmonary disease (COPD) is a risk factor for RP [17–20],
while others showed that RP was less severe in patients with more serious COPD than in
patients with normal lung function [21, 22]. Our study is in line with the latter. Some previous
studies assessing risk factors for RP [9, 23, 24] showed that emphysematous lesions decreased
the risk of RP, which is in line with our results. While we used high attenuation area in the
Table 2. Clinical parameters in symptomatic radiation pneumonitis patients and asymptomatic esophageal cancer patients.
Characteristic Symptomatic Patients (N = 8) Asymptomatic Patients (N = 64) P-value
Median age (range), year 69.5 (64–80) 71 (48–89) 0.907
Male sex 7 (87.5) 56 (87.5) 1.000
Disease stage 0.905
0 0 (0) 1 (1.6)
1 1 (12.5) 7 (10.9)
2 0 (0) 8 (12.5)
3 4 (50.0) 30 (46.9)
4 3 (37.5) 18 (28.1)
�Histology type 0.325
SqCC 7 (87.5) 59 (92.2)
Adenocarcinoma 0 (0) 3 (4.7)
Unknown 1 (12.5) 1 (1.6)
Others 0 (0) 1 (1.6)
Chemotherapy 0.585
Yes 8 (100) 56 (87.5)
No 0 (0) 8 (12.5)
Smoking history 0.036
Current 0 (0) 22 (34.4)
Former 8 (100) 34 (53.1)
Never 0 (0) 8 (12.5)
Smoking (range), pack-years 44.5 (35–60) 39 (0–159) 0.337
Median BMI (range), kg/m2 21.99 (15.63–25.37) 19.59 (14.19–28.56) 0.282
ILD 1.000
Yes 1 (12.5) 9 (14.1)
No 7 (87.5) 55 (85.9)
Median MLD (IQR), Gy 14.43 (10.039–19.258) 9.637 (7.096–11.884) 0.007
Median V20 (IQR) 26.868 (15.349–37.984) 14.911 (10.150–24.238) 0.029
Median LAV% (IQR) 4.6 (0.598–9.032) 10.781 (2.989–22.868) 0.082
�Percentages in this column may not add up to exactly 100% because of rounding.
Unless otherwise specified, data are expressed as numbers of patients, and numbers in parentheses are percentages. RP = radiation pneumonitis; SqCC = squamous cell
carcinoma; SCC = small cell carcinoma; NSCC = non-small cell carcinoma; BMI = body mass index; ILD = interstitial lung disease; MLD = mean lung dose;
IQR = interquartile range; V20 = percentage of lung volume irradiated� 20 Gy; LAV% = ratio of low attenuation volume to the lung volume.
https://doi.org/10.1371/journal.pone.0244143.t002
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Fig 2. Comparison of the AUC of dose-volume histogram parameters and RP in lung cancer and esophageal cancer. Black bars indicate the
three best DVH parameters. MLD, HAV30%, and HAV20% were the best three parameters in lung cancer, and HAV10%, HAV5%, and V10 were
the three best in esophageal cancer.
https://doi.org/10.1371/journal.pone.0244143.g002
Fig 3. Threshold of each DVH parameter for the prediction of symptomatic RP. Black bars represent esophageal cancer, and gray bars represent
lung cancer. The same scores were obtained for HAV30% in both esophageal cancer and lung cancer.
https://doi.org/10.1371/journal.pone.0244143.g003
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present study, these previous studies considered the low attenuation area; these have almost
the same meaning because the threshold limit of CT value (−856 HU) is the same. The mea-
surement of dose volume using high attenuation area is a very easy and convenient way to pre-
dict RP and may be widely applicable. In clinical trials, traditional DVH parameters excluding
high attenuation from consideration were used as the standard to avoid RP without doubting
their predictive accuracy for RP. To make every possible effort to avoid RP, DVH parameters
with high attenuation might be used better when treating lung cancer and esophageal cancer
patients.
We used –856 HU as the threshold [10, 25–28]. CT scans were performed under free
breathing, meaning they are almost equal to expiratory CT scans. We previously validated that
the LAV in inspiratory CT was highly associated with the LAV in CT under free breathing [9].
In our study, four lung cancer patients were treated with intensity-modulated radiotherapy.
The type of irradiation used for treatment was not significantly associated with the onset of
RP. Whether intensity-modulated radiotherapy increases or decreases the risk of RP has not
been clarified. Immune checkpoint inhibitor treatment used during or after chemotherapy
increases the risk of RP [16]; therefore, this problem must be verified in the future.
This study has several limitations that require further evaluation. First, our sample sizes
were relatively small in both groups, and the subjects were enrolled from a single institution.
This was also a retrospective study. A prospective multicenter study is needed to confirm the
presented results. Second, in our previous study [9], we adjusted our analysis for ILD and che-
motherapy, but we did not in this study. The purpose of this study was to evaluate the best
Fig 4. Comparison of the differences in threshold of each DVH parameter predicting symptomatic RP between lung cancer and esophageal cancer. Gray bars
indicate DVH parameters associated with high attenuation lung volume, and black bars indicate traditional DVH parameters. All DVH parameters associated with high
attenuation lung volume (gray bars) were smaller than their counterpart traditional DVH parameters (black bars). The difference in HAV30% was zero.
https://doi.org/10.1371/journal.pone.0244143.g004
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DVH parameters that can be used in the real-world setting; therefore, we simply compared the
threshold of DVH parameters for the prediction of RP. Another clinical element separate from
DVH parameters may affect the onset of RP. For example, chemotherapy and ILD were signifi-
cantly associated with the onset of symptomatic RP in lung cancer (Table 1). We also believe
that it is necessary to evaluate these parameters in other malignancies, such as breast cancer
and mediastinal tumors. Inspiration-breath-hold scans commonly used for SBRT lung radio-
therapy treatments would have larger LAV%, and hence, larger differentials between the seg-
mented and non-segmented metrics. The number of patients who have undergone IMRT is
small. This can potentially introduce bias since static IMRT or VMAT plans can have higher, if
not much higher, low dose contribution to the treatment. In other words, if the portion of the
IMRT plan increases, we may see the optimal dose evaluation criteria shift toward a low dose.
The 75% percentiles of HAV20% and V20 and V5 in esophageal cancer were lower than the
threshold; therefore, comparing these may not be of much significance.
Conclusions
DVH parameters with a high attenuation area may have higher commonality than conven-
tional DVH parameters in lung cancer and in esophageal cancer populations. HAV30% may
be a better DVH parameter for predicting RP than other conventional parameters.
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